DREAM PLANT

Within your reach.
Built for your success.

Plant 5 capacity

180KL

Operational in April 2025

S-CHOice®, Samsung Biologics' proprietary technology platform
DREAM PLANT - Plant5

BIO CAMPUSⅡ

BIO CAMPUSⅡ : 720KL

PLANT5 180KL

OPEN INNOVATION

PLANT6 180KL

PLANT7 180KL

PLANT8 180KL

PLANT5 DREAM PLANT

within your reach.

Built for your success.

BIO CAMPUSⅠ

BIO CAMPUSⅡ

PLANT5

  • Speed to Market
  • Integrated Design
  • Fully Automated
  • Sustainable Systems

Operational in April 2025

Drive. For Life.

SAMSUNG BIOLOGICS

  • Speed to Market

  • Integrated Design

  • Fully Automated

  • Sustainable Systems

Bio Campus II

Projected to be fully completed by 2032, our centralized Bio Campus II will enable our clients to close the gap between demand and supply of life-saving biologics.

Connectability
  • Center spine connecting all facilities with automated logisitics
Accessibility
  • Flexible and standardized operating procedures for all plants leveraging modular layout
Digitalization
  • Fully digitalized systems to offer seamless, transparent client communication
Additional 720KL by 2032 Additional 720KL by 2032

Related Contents

Samsung Biologics Amplifies “Sustainable Partnership” | Highlights from 2023 BIO International Convention Image
Samsung BIO Insight

Samsung Biologics Amplifies “Sustainable Partnership” | Highlights from 2023 BIO International Convention

June 9, 2023
At 2023 BIO International Convention in Boston, Samsung Biologics consolidated its presence as a “Sustainable Partner” by showcasing its continued commitment to sustainability with an eco-friendly booth while introducing its plans to expand the capacity and portfolio to further support its clients.
Samsung Biologics joins strategic investment in Araris to support collaboration in ADC therapies Image
News Brief

Samsung Biologics joins strategic investment in Araris to support collaboration in ADC therapies

April 12, 2023
Samsung Life Science Fund, created jointly between Samsung Biologics (KRX: 207940.KS) and Samsung C&T, and managed by Samsung Ventures, makes investment in Araris Biotech AG, a company pioneering a proprietary antibody-drug conjugate (ADC)-linker technology.
Samsung Biologics holds opening ceremony for its New Jersey site Image
News Brief

Samsung Biologics holds opening ceremony for its New Jersey site

March 21, 2023
On March 19th, Samsung Biologics held the official opening ceremony for its regional office in Ridgefield Park, New Jersey, which will provide streamlined communication and support to clients based in the U.S. and Europe. CEO John Rim and other Samsung leaders were in attendance for the ribbon-cutting, reaffirming the company’s commitment to delivering world-class services to current and potential clients worldwide.
Samsung Biologics announces construction of Plant 5 to commence Bio Campus II capacity expansion Image
Press Releases

Samsung Biologics announces construction of Plant 5 to commence Bio Campus II capacity expansion

April 26, 2023
​Incheon, S. Korea, March 17, 2023 – Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), announced today that the company will commence the construction of a fifth plant as part of its strategic expansion in response to increased market demand.
Samsung Biologics to attend DCAT Week, expand U.S. presence with New Jersey site Image
News Brief

Samsung Biologics to attend DCAT Week, expand U.S. presence with New Jersey site

March 21, 2023
Samsung Biologics is participating in DCAT Week 2023 from March 20 to 23. Kevin Sharp, VP and Head of Samsung Biologics America Sales, will talk about the company’s manufacturing capacity expansion plans in a speaking session during the Member Company Announcement Forum at the event.
Samsung Biologics shares 2023 business plans at 41st Annual J.P. Morgan Healthcare Conference Image
News Brief

Samsung Biologics shares 2023 business plans at 41st Annual J.P. Morgan Healthcare Conference

January 12, 2023
Samsung Biologics shared its 2023 business plans and vision at the 41st Annual J.P. Morgan Healthcare Conference, taking place between January 9-12 in San Francisco, California, USA. During the main track presentation today, John Rim, CEO and President of Samsung Biologics said the company will build on the strong growth momentum in 2022 with continued investments to further solidify its global position.
#CPHI22: As Samsung’s new plant comes online, it looks to expand in Korea and beyond Image
Media Focus

#CPHI22: As Samsung’s new plant comes online, it looks to expand in Korea and beyond

December 2, 2022
It is no secret that the CDMO arm of one of South Korea’s largest conglomerates has been expanding in 2022. In the middle of the year, Samsung Biologics was going to see a bump in funding from the Samsung group and now has committed to boosting its presence in South Korea and beyond.
Samsung Biologics unlocks additional capacity for production at its newest Plant 4 Image
Press Releases

Samsung Biologics unlocks additional capacity for production at its newest Plant 4

October 11, 2022
Incheon, S. Korea, October 11, 2022 – Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), announced today that its Plant 4 – the world’s largest single bio manufacturing plant – has commenced GMP operations this month.
For $323M, Samsung Biologics buys land for a 2nd manufacturing campus in South Korea Image
Media Focus

For $323M, Samsung Biologics buys land for a 2nd manufacturing campus in South Korea

August 5, 2022
Samsung’s expansion plan for its CDMO unit is an efficient, no-nonsense enterprise, marching on with no end in sight.
Maybe that’s why, at its home base in South Korea, Samsung Biologics refers to its factories by number. Just 11 years into its existence, Samsung has Plants 1, 2 and 3 in operation, Plant 4 under construction and Plants 5 and 6 on the drawing board.
Samsung Biologics speeds $2B plant build forecast to boost capacity 70% Image
Media Focus

Samsung Biologics speeds $2B plant build forecast to boost capacity 70%

August 10, 2022
Samsung Biologics is pushing for early completion of its new $2 billion manufacturing facility in an effort to meet increased demand and boost the South Korean CMO giant’s profits.

SITE MAP

close
Close

Your download is ready

Click Download.

Download
Close

Subscribe to Our Newsletter

Please fill in your details, select one or more areas of interest, and click the subscribe button to receive our newsletter.

Subscribe to Our Newsletter
  • Privacy Policy to collect the email address that I have provided until I withdraw my consent. The collected information will only be used for the purpose of mailing service. If you do not wish to consent, you will not be able to receive the newsletter. Samsung Biologics respects the privacy of its subscribers.
Close

Please fill out the form
to view the full content

Please sign up to view the post..
* Required
Privacy Policy
close

COOKIE POLICY

초점받기 링크
Last Updated: [31 Mar 2023]

This Cookie Policy applies to the Samsung Biologics website (the “Website”). Please read this Cookie Policy carefully and feel free to contact us if you have any questions.

Your Privacy
- What are cookies?

A cookie is a small text file that a website saves on your computer or mobile device when you visit the Website. It enables the Website to remember your actions and preferences (such as language preferences) over a period of time, so you don't have to keep re-entering them whenever you come back to the Website or browse from one page to another.

- How to control cookies

You can control and/or delete cookies as you wish - for details, see http://www.aboutcookies.org. You can delete all cookies that are already on your computer and you can set most browsers to prevent them from being placed. If you do this, however, you may have to manually adjust some preferences every time you visit a site and some services and functionalities may not work.

Strictly Necessary
Cookies
Always Active

These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.

Performance
Cookies

These cookies are used to collect information about how visitors use our website. We use the information to compile reports and to help us improve the website. The cookies collect information in an anonymous form, including the number of visitors to the website, where visitors have come to the website from and the pages they visited.

Google Analytics

This website uses Google Analytics, a website analytics service provided by Google, Inc. (“Google”). Google Analytics uses cookies and the information generated by the cookie is usually transmitted to a Google server in the USA and stored there.

You can prevent Google’s collection of the data generated by the cookie and related use of the website, including your IP address, as well as the processing of such data by Google by downloading and installing the browser plug-in available under the following link: http://tolls.google.com/dlpage/gaoptout.

Targeting
Cookies

These Cookies are used by advertising companies to inform and serve personalized ads more relevant to your interests. These Cookies also may facilitate sharing information with social networks or recording your interactions with particular ads.

We currently do not use any cookies in this category

close

SECURITY REPORT

Your valuable comments contribute to protecting Samsung Biologic’s core technology and management information, as well as reinforcing domestic competency and economic development.

  • This page is created for reporting core technology and management information leakage.
  • The reported contents as well as the identity of the reporter are strictly secured.
THE MANUAL FOR SECURITY NOTIFICATION
E-mail sbl.infosec@samsung.com